comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 00:48:04 - browse：74142

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Achieving telehealth equity for people with hearing loss

WSS

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

J&J reports mixed data on next

Dario to buy mental health app maker Twill in cash and stock deal

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

hotspot

comprehensive

explore

Bright Health sells Medicare Advantage business to Molina

Dario to buy mental health app maker Twill in cash and stock deal

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The world needs the new pandemic treaty

As demand for Covid shots wanes, Moderna seeks its next success

Why we need mandatory labeling of GMO products

Supreme Court strikes down use of affirmative action

J&J reports mixed data on next

Medicare details structure of new drug price negotiation program

Why we need mandatory labeling of GMO products

explore

Alabama IVF ruling threatens families facing fatal genetic disease

Louisiana bill approved classifying abortion pills as controlled substances

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

A new nitrogen execution bill also undermines medical licensing

Antivenom research: Lessons from HIV applied in search for universal antidote

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

leisure time

Wikipedia

leisure time

focus